Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia Response

被引：1
|
作者：
Butterworth, Michael [1 ]
Vogler, Meike [1 ]
Dyer, Martin J. S. [1 ]
Cohen, Gerald M. [1 ]
机构：
[1] Univ Leicester, MRC Toxicol Unit, Leicester LE1 9HN, Leics, England
来源：
BLOOD | 2009年 / 114卷 / 12期
关键词：
PROLIFERATION; INHIBITORS; APOPTOSIS; LYMPHOMA; BALANCE; CXCR4; CELLS;
D O I：
10.1182/blood-2009-07-232926
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2561 / 2562
页数：4
相关论文
共 50 条
  • [41] Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia
    Del Giudice, Ilaria
    Della Starza, Irene
    De Falco, Filomena
    Gaidano, Gianluca
    Sportoletti, Paolo
    CANCERS, 2024, 16 (11)
  • [42] Marked sensitivity of chronic lymphocytic leukemia (CLL) to apoptosis induced by BCL2 antagonist ABT-737.
    Vogler, Meike
    Majid, Aneela
    Walewska, Renata
    Dyer, Martin J. S.
    Cohen, Gerald M.
    BLOOD, 2007, 110 (11) : 913A - 913A
  • [43] THE BCL-2 ANTAGONIST ABT-737 IS HIGHLY EFFECTIVE ON PRIMARY ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
    Decandia, S.
    Ricciardi, M. R.
    Santinelli, S.
    De Cave, F.
    Gregorj, C.
    Bergamo, P.
    Libotte, F.
    Vitale, A.
    Petrucci, M. T.
    Milella, M.
    Foa, R.
    Tafuri, A.
    HAEMATOLOGICA, 2008, 93 : S83 - S83
  • [44] ABT-737 and ABT-199 complement the multikinase inhibitor TG02 to induce apoptosis in acute myeloid leukemia cells
    Abdul-Aziz, Amina
    Burrows, Francis
    Yu, Ning
    Russell, Nigel H.
    Seedhouse, Claire H.
    Pallis, Monica
    CANCER RESEARCH, 2014, 74 (19)
  • [45] Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin–NFAT pathway
    P E Cippà
    A K Kraus
    M T Lindenmeyer
    J Chen
    A Guimezanes
    P D Bardwell
    T Wekerle
    R P Wüthrich
    T Fehr
    Cell Death & Disease, 2012, 3 : e299 - e299
  • [46] The Tumor Microenvironment-Dependent Transcription Factors AHR and HIF-1α Are Dispensable for Leukemogenesis in the Eμ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia
    Gonder, Susanne
    Largeot, Anne
    Gargiulo, Ernesto
    Pierson, Sandrine
    Botana, Iria Fernandez
    Pagano, Giulia
    Paggetti, Jerome
    Moussay, Etienne
    CANCERS, 2021, 13 (18)
  • [47] Effective cell killing of primary acute lymphoblastic leukemia cells by the BCL-2 antagonist ABT-737
    Tafuri, A.
    Ricciardi, M. R.
    Gregorj, C.
    De Cave, F.
    Santinelli, S.
    Bergamo, P.
    Decandia, S.
    Vitale, A.
    Petrucci, M. T.
    Milella, M.
    Foa, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 5 - 6
  • [48] Cytotoxicity, Drug Combinability, and Biological Correlates of ABT-737 Against Acute Lymphoblastic Leukemia Cells With MLL Rearrangement
    Jayanthan, Aarthi
    Incoronato, Andrea
    Singh, Anjali
    Blackmore, Christopher
    Bernoux, Delphine
    Lewis, Victor
    Stam, Ronald
    Whitlock, James A.
    Narendran, Aru
    PEDIATRIC BLOOD & CANCER, 2011, 56 (03) : 353 - 360
  • [49] Targeting the tumor microenvironment in chronic lymphocytic leukemia
    Svanberg, Rebecka
    Janum, Sine
    Patten, Piers E. M.
    Ramsay, Alan G.
    Niemann, Carsten U.
    HAEMATOLOGICA, 2021, 106 (09) : 2312 - 2324
  • [50] Alterations Of The Chemokine Microenvironment In Chronic Lymphocytic Leukemia
    Seiler, Till M.
    Aydin, Roland
    Herold, Tobias
    Holdenrieder, Stefan
    Hallek, Michael
    Hiddemann, Wolfgang
    Dreyling, Martin
    Bergmann, Manuela A.
    BLOOD, 2013, 122 (21)
12345